The Global Fund is a 21st century partnership organization designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. Founded in 2002, the Global Fund is a partnership between governments, civil society, the private sector and people affected by the diseases. The Global Fund raises and invests nearly US$4 billion a year to support programs run by local experts in countries and communities most in need.
As a financing institution, GFATM provides support to countries where programs are implemented. By challenging barriers and embracing innovative approaches, the Global Fund partnership strives for maximum impact. Since its creation in 2002, GFATM has contributed to save millions of lives and provided prevention, treatment and care services to hundreds of millions of people, helping to revitalize entire communities, strengthen local health systems and improve economies.
Recent report shows with the Global Fund partnership greater results were achieved by 2015. Cumulative progress since the Global Fund was created in 2002 demonstrates a result oriented partnership, a collective effort, combining the strong contributions made by governments, civil society, the private sector and people affected by HIV, TB and malaria. Cumulative highlights show that: 17 million lives saved; on track to reach 22 million lives saved by the end of 2016 A decline of one-third in the number of people dying from HIV, TB and malaria since 2002, in countries where the Global Fund invests 8.1 million people on antiretroviral treatment for HIV 13.2 million people have received TB treatment 548 million mosquito nets distributed through programs for malaria.1
As far as HIV is concerned, in 2015, the world delivered on the AIDS targets of Millennium Development Goal 6 halting and reversing the AIDS epidemic. By mid-2015, the number of people accessing antiretroviral therapy reached nearly 16 million doubles the number just five years earlier. The World has committed to Ending AIDS by 2030 as an integral part of the Sustainable Development Goals, which United Nations Member States adopted unanimously in 2015.
Ensuring the success of the Sustainable Development Goals, including ending the AIDS epidemic, will require global solidarity and partnership, especially in times of diverse and demanding global challenges. Focus and increase of financial resources are to remain strong to build a more sustainable world by 2030. Based on the above mentioned context we believe that in a bid to end HIV, TB and malaria as epidemics, increasing domestic and donors finances for health is tremendously important.
In October/November this year, The Global Fund will host a fundraising conference where countries will announce their new pledges for the 2017 – 2019’ cycle. This conference is referred to as the 5th Replenishment Round. For the 5th Replenishment Round, the Fund targets to mobilize $13 billion at the bare minimum. Due to reductions in donor pledges, the Global Fund hasn’t hit its fundraising targets since 2010. If this target is not met, the Fund may have to close some treatment programs and turn away those in need!
Major donor agencies such as the World Bank have been financing HIV prevention, treatment and care programs as well as supporting countries to do “better for less” have specifically provided technical assistance to increase the efficiency, effectiveness and sustainability of national responses to the epidemics (HIV, TB and Malaria) which are acute especially in Sub-Saharan Africa .Of the 10 countries with the highest HIV prevalence in the world, all of them located in Sub-Saharan Africa, 7 are considered Middle income countries (MICs). Majority of Africa’s people living with HIV reside in countries that are no longer ‘poor’ according to the WB scale. This classification system is being used by entities outside of the World Bank in ways that go beyond its intended analytical purposes. The GF for example, uses the World Bank country groups to set progressively lower funding levels for Middle and Low Income Countries.
Pharmaceutical companies set tiered pricing on medicines, making them more expensive for MICs e.g. Atripla, a brand name version of a first line ARV costs $613 per patient per year for low income countries (LICs) and $1,033 ppy for MICs. Donors are using the MIC label to justify funding cutbacks and increase number of countries eligible for foreign assistance2.
It is in that context that with the approach of the Fifth Replenishment Round of the Global Fund planned to take place later this year, AIDS Healthcare Foundation (AHF) in partnership with other Civil Society Groups launched a worldwide “Fund the Fund” campaign, which calls on donor countries to commit to fully funding the Global Fund for 2017-2019 grant’ cycle.
Objectives of the meeting
The goal of this High level Round table discussion on Sustainable Financing is to advance the advocacy for the increase of domestic and donor funding package to end AIDS, TB and Malaria. Specific objectives of the meeting include:
Provide up to date information on the GFATM and gains towards ending the three diseases (AIDS, TB and Malaria)
Provide an opportunity to discuss the shared responsibility and advocacy messages for the world’s five largest economies to increase contributions to GFATM in its 5th Replenishment; to lead by example and inspire other donors to do more.
Discuss way forward in this journey of advocacy
Increase awareness on GFATM achievements and gaps towards ending AIDS, TB and Malaria in alignment with the SDGs targets
Strategies to increase and sustain funding for ending the three diseases with a particular focus to the world’s five largest economies are developed
Mechanisms for full inclusion and participation of civil society organizations in the response to the three diseases (AIDS, TB and Malaria) are designed,
CSOs’ concept note to advance advocacy efforts with specific timeline is developed